Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$6.17
-0.42-6.37%
At close: -
$7.45
1.2820.75%
After Hours: Mar 25, 7:36 PM EDT
Comments
Loading...
Vicarious Surgical Analyst Ratings and Price Targets | NYSE:RBOT | Benzinga
Vicarious Surgical Inc has a consensus price target of $6.97 based on the ratings of 5 analysts. The high is $10 issued by Morgan Stanley on July 15, 2024. The low is $0.4 issued by Canaccord Genuity on November 14, 2023. The 3 most-recent analyst ratings were released by Piper Sandler on March 18, 2025, November 13, 2024, and August 13, 2024, respectively. With an average price target of $10.33 between Piper Sandler, there's an implied 38.70% upside for Vicarious Surgical Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Piper Sandler
Morgan Stanley
Canaccord Genuity
Canaccord Genuity
1calculated from analyst ratings
Analyst Ratings for Vicarious Surgical
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/18/2025 | Buy Now | 14.09% | Piper Sandler | Adam Maeder65% | $10.5 → $8.5 | Maintains | Neutral | Get Alert |
| 11/13/2024 | Buy Now | 40.94% | Piper Sandler | Adam Maeder65% | $12 → $10.5 | Maintains | Neutral | Get Alert |
| 08/13/2024 | Buy Now | 61.07% | Piper Sandler | Adam Maeder65% | $30 → $12 | Maintains | Neutral | Get Alert |
| 07/15/2024 | Buy Now | 34.23% | Morgan Stanley | Patrick Wood53% | $18 → $10 | Maintains | Equal-Weight | Get Alert |
| 03/05/2024 | Buy Now | -86.58% | Piper Sandler | Adam Maeder65% | $45 → $30 | Maintains | Neutral | Get Alert |
| 12/04/2023 | Buy Now | -91.95% | Morgan Stanley | Patrick Wood53% | → $18 | Initiates | → Equal-Weight | Get Alert |
| 11/14/2023 | Buy Now | — | BTIG | Ryan Zimmerman73% | — | Downgrade | Buy → Neutral | Get Alert |
| 11/14/2023 | Buy Now | -94.63% | Canaccord Genuity | Caitlin Cronin49% | $270 → $12 | Downgrade | Buy → Hold | Get Alert |
| 05/31/2023 | Buy Now | 20.81% | Canaccord Genuity | Kyle Rose66% | $360 → $270 | Maintains | Buy | Get Alert |
| 07/18/2022 | Buy Now | -6.04% | BTIG | Ryan Zimmerman73% | $240 → $210 | Maintains | Buy | Get Alert |
| 05/10/2022 | Buy Now | -32.89% | Piper Sandler | Adam Maeder65% | $210 → $150 | Maintains | Neutral | Get Alert |
FAQ
What is the target price for Vicarious Surgical (RBOT) stock?
The latest price target for Vicarious Surgical (NYSE:RBOT) was reported by Piper Sandler on March 18, 2025. The analyst firm set a price target for $8.50 expecting RBOT to rise to within 12 months (a possible 14.09% upside). 4 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Vicarious Surgical (RBOT)?
The latest analyst rating for Vicarious Surgical (NYSE:RBOT) was provided by Piper Sandler, and Vicarious Surgical maintained their neutral rating.
When was the last upgrade for Vicarious Surgical (RBOT)?
There is no last upgrade for Vicarious Surgical
When was the last downgrade for Vicarious Surgical (RBOT)?
The last downgrade for Vicarious Surgical Inc happened on November 14, 2023 when BTIG changed their price target from N/A to N/A for Vicarious Surgical Inc.
When is the next analyst rating going to be posted or updated for Vicarious Surgical (RBOT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Vicarious Surgical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Vicarious Surgical was filed on March 18, 2025 so you should expect the next rating to be made available sometime around March 18, 2026.
Is the Analyst Rating Vicarious Surgical (RBOT) correct?
While ratings are subjective and will change, the latest Vicarious Surgical (RBOT) rating was a maintained with a price target of $10.50 to $8.50. The current price Vicarious Surgical (RBOT) is trading at is $7.45, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.